Concentrix Earnings Calls
| Release date | Jun 25, 2026 |
| EPS estimate | $2.64 |
| EPS actual | - |
| Revenue estimate | 2.474B |
| Revenue actual | - |
| Expected change | +/- 6.10% |
| Release date | Mar 24, 2026 |
| EPS estimate | $2.64 |
| EPS actual | $2.61 |
| EPS Surprise | -1.14% |
| Revenue estimate | 2.493B |
| Revenue actual | 2.5B |
| Revenue Surprise | 0.312% |
| Release date | Jan 13, 2026 |
| EPS estimate | $2.91 |
| EPS actual | $2.95 |
| EPS Surprise | 1.37% |
| Revenue estimate | 2.54B |
| Revenue actual | 2.553B |
| Revenue Surprise | 0.524% |
| Release date | Sep 25, 2025 |
| EPS estimate | $2.88 |
| EPS actual | $2.78 |
| EPS Surprise | -3.47% |
| Revenue estimate | 2.46B |
| Revenue actual | 2.483B |
| Revenue Surprise | 0.95% |
Last 4 Quarters for Concentrix
Below you can see how CNXC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 25, 2025 |
| Price on release | $54.99 |
| EPS estimate | $2.88 |
| EPS actual | $2.78 |
| EPS surprise | -3.47% |
| Date | Price |
|---|---|
| Sep 19, 2025 | $56.97 |
| Sep 22, 2025 | $55.53 |
| Sep 23, 2025 | $55.09 |
| Sep 24, 2025 | $55.60 |
| Sep 25, 2025 | $54.99 |
| Sep 26, 2025 | $47.66 |
| Sep 29, 2025 | $47.83 |
| Sep 30, 2025 | $46.15 |
| Oct 01, 2025 | $48.22 |
| 4 days before | -3.48% |
| 4 days after | -12.31% |
| On release day | -13.33% |
| Change in period | -15.36% |
| Release date | Jan 13, 2026 |
| Price on release | $39.18 |
| EPS estimate | $2.91 |
| EPS actual | $2.95 |
| EPS surprise | 1.37% |
| Date | Price |
|---|---|
| Jan 07, 2026 | $42.89 |
| Jan 08, 2026 | $44.07 |
| Jan 09, 2026 | $44.06 |
| Jan 12, 2026 | $40.48 |
| Jan 13, 2026 | $39.18 |
| Jan 14, 2026 | $41.42 |
| Jan 15, 2026 | $42.18 |
| Jan 16, 2026 | $43.15 |
| Jan 20, 2026 | $40.11 |
| 4 days before | -8.65% |
| 4 days after | 2.37% |
| On release day | 5.72% |
| Change in period | -6.48% |
| Release date | Mar 24, 2026 |
| Price on release | $26.48 |
| EPS estimate | $2.64 |
| EPS actual | $2.61 |
| EPS surprise | -1.14% |
| Date | Price |
|---|---|
| Mar 18, 2026 | $30.78 |
| Mar 19, 2026 | $31.92 |
| Mar 20, 2026 | $31.52 |
| Mar 23, 2026 | $33.04 |
| Mar 24, 2026 | $26.48 |
| Mar 25, 2026 | $24.67 |
| Mar 26, 2026 | $27.72 |
| Mar 27, 2026 | $26.42 |
| Mar 30, 2026 | $26.68 |
| 4 days before | -13.97% |
| 4 days after | 0.755% |
| On release day | -6.84% |
| Change in period | -13.32% |
| Release date | Jun 25, 2026 |
| Price on release | - |
| EPS estimate | $2.64 |
| EPS actual | - |
| Date | Price |
|---|---|
| May 28, 2026 | $26.48 |
| May 29, 2026 | $28.29 |
| Jun 01, 2026 | $30.03 |
| Jun 02, 2026 | $28.49 |
| Jun 03, 2026 | $27.68 |
Concentrix Earnings Call Transcript Summary of Q1 2026
Concentrix reported Q1 FY2026 revenue of ~$2.5 billion, up 1.9% on a constant currency basis (over 5% reported). Key growth drivers were banking & financial services (+13%) and retail/travel/e-commerce (+6%); technology/consumer electronics and health care were down ~6% due to lighter volumes and shore mix. The company is seeing strong demand for AI-powered solutions: technology-related wins rose >61% YoY, signed annual contract value for solutions (including AI) more than doubled quarter-on-quarter, and iX suite deal momentum included ~60 enterprise iX deals (two Fortune 50 Hero deals). Non-GAAP operating income was $295 million and adjusted EBITDA was $348 million (13.9% margin); non-GAAP diluted EPS was $2.61, in line with prior guidance. Adjusted free cash flow was negative $145 million in Q1 due to seasonal AR timing (collected in early March), and Concentrix reiterates full-year adjusted free cash flow guidance of $630–$650 million. Management is executing cost actions and restructuring expected to yield ~$40 million of annualized savings and expects sequential margin expansion in H2 2026; Q2 revenue guidance is $2.46–$2.485 billion with non-GAAP operating income of $290–$300 million. The company raised $600 million of 3-year notes to manage maturities, ended Q1 with ~$234 million cash and ~$4.75 billion debt (net debt ~$4.51B), and targets net leverage below 2.6x adjusted EBITDA by year-end. Management emphasized continued investment in proprietary AI (iX suite), third-party tech partnerships, and pursuing higher-value, transformational deals that may compress margins early but are accretive at scale.
Sign In
Buy CNXC